Svoronos Dawn 4
4 · Xenon Pharmaceuticals Inc. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Xenon (XENE) Director Dawn Svoronos Receives RSU Vesting; Taxes Withheld
What Happened
Dawn Svoronos, a director of Xenon Pharmaceuticals (XENE), had a prior RSU award (granted 6/5/2025) vest 100% on June 1, 2026, converting into 2,645 common shares. To satisfy income tax withholding on that vesting, the issuer withheld 1,416 shares (valued at the June 1 closing price of $53.41, ≈ $75,629). On June 3, 2026 the company granted the reporting person two RSU awards totaling 12,100 RSUs (10,507 and 1,593 RSUs) that vest 100% on the earlier of June 1, 2027 or the day before the 2027 annual meeting.
Key Details
- Transaction dates: vesting/settlement on 2026-06-01; new RSU grants on 2026-06-03. Filing date: 2026-06-03 (appears timely).
- Vesting: 2,645 shares vested on 6/1/2026; 1,416 of those were withheld for taxes (net delivered shares = 1,229). Withheld-share value reported at $53.41/share → ~$75,629.
- New awards: 10,507 RSUs and 1,593 RSUs granted on 6/3/2026 (total 12,100 RSUs); each RSU converts to one share and vests 100% by June 1, 2027 (or before the 2027 annual meeting).
- Footnotes: withholding represents tax remittance in a net settlement and is not a sale. RSU grants are derivative awards (contingent right to shares).
- Shares owned after the transactions: not specified in the provided filing excerpt.
Context
This activity is primarily administrative: an RSU award vested and was net-settled for tax withholding (common practice), and new RSUs were granted with a one-year vesting horizon. The withholding of shares to cover taxes does not indicate an open-market sale. New RSU grants are future-compensation awards and do not represent an immediate purchase or sale of stock.
Insider Transaction Report
- Exercise/Conversion
Common Shares
[F1]2026-06-01+2,645→ 27,645 total - Tax Payment
Common Shares
[F2][F3]2026-06-01$53.41/sh−1,416$75,629→ 26,229 total - Exercise/Conversion
Restricted Share Units
[F1]2026-06-01−2,645→ 0 total→ Common Shares (2,645 underlying) - Award
Share Option (Right to Buy)
[F4]2026-06-03+10,507→ 10,507 totalExercise: $53.46Exp: 2036-06-02→ Common Shares (10,507 underlying) - Award
Restricted Share Units
[F5]2026-06-03+1,593→ 1,593 totalExercise: $0.00→ Common Shares (1,593 underlying)
Footnotes (5)
- [F1]Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
- [F2]Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale.
- [F3]Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations.
- [F4]Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
- [F5]Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.